CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
- Seasonal flu vaccine candidate boosted antibody titers at all dose levels and for all
encoded seasonal influenza strains across younger and older adults - Potentially differentiated, multivalent candidate encodes antigens matched to all four
WHO-recommended flu strains - For influenza A strains, geometric mean titers numerically exceeded those elicited by
the licensed comparator vaccines consistently across all tested dose levels and age
groups - For influenza B strains, geometric mean titers were lower than those elicited by the
licensed comparator vaccines, in line with expectations and other initial mRNA-based
clinical flu development programs - Further optimizations to enhance immune responses against influenza B strains will be
tested in additional Phase 2 study - Candidate showed acceptable safety profile, confirming previous findings that the
proprietary platform elicits strong overall antibody titers at well-tolerated dose levels
CureVac N.V. (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced interim data from an ongoing Phase 2 part of the combined Phase 1/2 study of its seasonal influenza vaccine candidate, conducted in collaboration with GSK. The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate. It was designed for broad antigen coverage, encoding antigens matched to all four WHO-recommended flu strains.